Through pop-up clinics held at a London school, Crick scientists are investigating the growing overlap of hepatitis B and metabolic liver disease.

Europe is set to miss the WHO target to eliminate viral hepatitis as a public health threat by 2030 despite progress in screening because of gaps in vaccination and reaching key populations, according...

England is on track to become one of the first countries in the world to eliminate hepatitis C, a dangerous virus that attacks the liver, figures show.

Our findings provide the first robust national-level evidence, albeit observational, that high HPV vaccination coverage is associated with a substantial reduction in cervical cancer deaths. This is sh...

An exciting shift is underway in progress towards tackling HIV as a global public health threat, as we enter a new era of nucleotide and nucleoside reverse transcriptase inhibitor (NRTI)-free dual reg...

BRATISLAVA, June 9 (IPS) - As South Africa officially launches the rollout of a groundbreaking HIV prevention drug, civic groups in the country have slammed the plan, saying it will not reach anywhere near enough people.

New research from the Clinton Health Access Initiative shows declines in HIV testing and in people accessing oral prevention services.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain public health threats in the WHO European region, where an estimated 29 million people live with chronic infection and viral hepatitis-relate...

This is a poster to describe the population of people living with chronic Hepatitis B (PLHBV) who are accessing HIV pre-exposure prophylaxis (also known as PrEP) from Mortimer Market (London, UK), where our service provides care for people living with chronic (long-term) viral infections.These individuals may benefit from Tenofovir-based combination antiretroviral therapy for both HBV treatment HIV PrEP, and the benefits of PrEP are yet to be fully realised in this population.This information is helpful in shaping future ideas on how to provide wider/holistic care for PLWHB

Martyn et al collate evidence for identifying metabolic dysfunction associated liver disease (MASLD) in people living with chronic hepatitis B virus infection. They highlight inconsistencies and gaps,...

The Hepatitis C Trust runs national projects where peers draw on their lived experience of drug use and hepatitis C to support others. We are now recruiting for a role to join our Bristol & Severn tea...

Background and Aims An estimated 270 000 people in the UK live with hepatitis B infection, the leading global cause of liver cancer. In 2022, opt-out hepatitis B testing was introduced in emergency .....

An estimated 1.1 million people died from hepatitis B and 240,000 from hepatitis C in 2024.

High-profile international targets have been set by WHO for the elimination of viral hepatitis as a public health threat by 2030.1 With 5 years remaining, now is an opportune moment to reflect on the ...